| 10/09/2026 3:53 PM | Jasper Therapeutics (1788028) Filer | Form PRE 14A | |
| 10/07/2026 7:05 AM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/07/2026 6:50 AM | Jasper Therapeutics (1788028) Subject | Form SC TO-I | |
| 10/05/2026 7:00 AM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/01/2026 4:29 PM | Jasper Therapeutics (1788028) Filer | Form 8-K/A | |
| 09/28/2026 3:44 PM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/24/2026 3:15 PM | Jasper Therapeutics (1788028) Subject Nasdaq Stock Market LLC (1354457) Filed by | Form 25-NSE | |
| 09/04/2026 2:08 PM | Jasper Therapeutics (1788028) Filer | Form DEF 14A | |
| 08/26/2026 3:15 PM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/24/2026 4:30 PM | Jasper Therapeutics (1788028) Filer | Form PRE 14A | |
| 08/14/2026 10:00 AM | Jasper Therapeutics (1788028) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
Get the Latest News and Ratings for JSPRW and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 08/03/2026 3:47 PM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/31/2026 5:06 AM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/22/2026 6:10 PM | Jasper Therapeutics (1788028) Issuer Ros Matthew E (1461613) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 07/22/2026 6:10 PM | Jasper Therapeutics (1788028) Issuer Song Wenru (2143140) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 07/22/2026 6:10 PM | Jasper Therapeutics (1788028) Issuer Ros Matthew E (1461613) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/20/2026 7:37 PM | Crutcher Patrick J (1754540) Reporting Jasper Therapeutics (1788028) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 07/20/2026 7:38 PM | Crutcher Patrick J (1754540) Reporting Jasper Therapeutics (1788028) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/20/2026 4:01 PM | Jasper Therapeutics (1788028) Subject Velan Capital Investment Management LP (1848809) Filed by | Form SCHEDULE 13D/A | |
| 07/16/2026 8:50 PM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/16/2026 4:15 PM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/10/2026 5:20 PM | INTEGRATED CORE STRATEGIES (0) US Jasper Therapeutics (1788028) Subject | Form SCHEDULE 13G/A | |
| 06/15/2026 3:03 PM | Jasper Therapeutics (1788028) Filer | Form DEF 14A | |
| 06/15/2026 3:03 PM | Jasper Therapeutics (1788028) Filer | Form DEFA14A | |
| 06/15/2026 3:05 PM | Jasper Therapeutics (1788028) Filer | Form ARS | |
| 06/09/2026 3:05 PM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/01/2026 7:01 AM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/14/2026 3:05 PM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/14/2026 3:05 PM | Jasper Therapeutics (1788028) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/12/2026 11:44 AM | Jasper Therapeutics (1788028) Subject MORGAN STANLEY (895421) Filed by | Form SCHEDULE 13G/A | |
| 05/08/2026 4:01 PM | Jasper Therapeutics (1788028) Subject Soleus Capital Master Fund, L.P. (1812275) Filed by | Form SCHEDULE 13G/A | |
| 05/08/2026 12:53 PM | GOLDMAN SACHS GROUP INC (886982) Filed by Jasper Therapeutics (1788028) Subject | Form SCHEDULE 13G/A | |
| 03/30/2026 4:33 PM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/25/2026 3:47 PM | INTEGRATED CORE STRATEGIES (0) US Jasper Therapeutics (1788028) Subject | Form SCHEDULE 13G | |
| 02/12/2026 9:33 AM | GOLDMAN SACHS GROUP INC (886982) Filed by Jasper Therapeutics (1788028) Subject | Form SCHEDULE 13G | |
| 02/11/2026 12:38 PM | Jasper Therapeutics (1788028) Subject MORGAN STANLEY (895421) Filed by | Form SCHEDULE 13G | |
| 01/26/2026 2:29 PM | ACORN BIOVENTURES, L.P. (1766853) Filed by Jasper Therapeutics (1788028) Subject | Form SCHEDULE 13G/A | |
| 01/08/2026 6:06 AM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/07/2026 3:35 PM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/05/2026 6:30 PM | CROSS HERB (1230721) Reporting Jasper Therapeutics (1788028) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/05/2026 6:30 PM | Jasper Therapeutics (1788028) Issuer Mahal Jeetinder Singh (1882877) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
INSANE DRONE FOOTAGE (Ad) New drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and built in a matter of weeks.
James Altucher says the site could go live as soon as October 21 and has put together a free presentation explaining what is happening inside and why the timing matters. Watch the free presentation before the October 21 deadline. |
| 01/05/2026 6:30 PM | Jasper Therapeutics (1788028) Issuer MARTELL RON (1177079) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/02/2025 9:23 AM | ACORN BIOVENTURES, L.P. (1766853) Filed by Jasper Therapeutics (1788028) Subject | Form SCHEDULE 13G | |
| 12/02/2025 6:06 AM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/14/2025 4:22 PM | Jasper Therapeutics (1788028) Subject Qiming U.S. Healthcare Fund II, L.P. (1765710) Filed by | Form SCHEDULE 13G/A | |
| 11/12/2025 12:04 PM | Jasper Therapeutics (1788028) Subject KINGDON CAPITAL MANAGEMENT, L.L.C. (1000097) Filed by | Form SCHEDULE 13G/A | |
| 11/10/2025 7:05 AM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/10/2025 7:17 AM | Jasper Therapeutics (1788028) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 11/07/2025 11:45 AM | Jasper Therapeutics (1788028) Subject MORGAN STANLEY (895421) Filed by | Form SCHEDULE 13G/A | |